Indivior PLC (LON:INDV – Get Free Report)’s stock price fell 15.7% on Thursday . The company traded as low as GBX 548.71 ($6.95) and last traded at GBX 732 ($9.28). 1,888,371 shares were traded during trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($11.00).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 1,800 ($22.81) price objective on shares of Indivior in a research note on Tuesday, December 17th.
Check Out Our Latest Stock Analysis on INDV
Indivior Stock Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to Invest in Insurance Companies: A Guide
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- What Do S&P 500 Stocks Tell Investors About the Market?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.